While more than $2.5 billion has flowed into kidney-focused value-based care over the past 5-6 years hospital spending on kidney disease has not improved. The problem may not be the dollar amount. What might be off is the target of the intervention.
The dominant kidney-care strategy has either been managing chronic disease prior to failure or improving dialysis delivery. Both are clinically important, but they miss the key moment that determines hospital costs: the hospitalization that pushes a CKD patient into acute kidney injury, triggering a cascade of events that drives up inpatient spending for years to come.
What the data showed
The February 2026 CMS evaluation of the Kidney Care Choices model makes a compelling case. The Lewin Group’s analysis of the KCC model found measurable clinical improvements, increased home dialysis adoption, and improved living donor transplant rates. But on the metric that matters most to hospital operators and taxpayers, there was no reduction in hospital spending, and net Medicare expenditures increased by approximately $305 million in the second year.
This is not a failure of intent or execution – the intervention was successfully implemented. It is a signal about leverage. The KCC model, like most kidney-focused VBC initiatives, was designed to reduce inpatient costs, the biggest target for reduced spending. Unfortunately, the increase in hospitalization rates happens much earlier in the course of the disease than the KCC targeted.
The acute event is where hospital economics are determined
When patients with chronic kidney disease, even undiagnosed, are admitted to the hospital, their kidneys are already operating with depleted reserve. Any acute stress event, such as cardiac surgery, heart failure, or sepsis, impacts blood flow, blood pressure and inflammatory response, further taxing the kidneys and compromising their ability to respond.
Recovery becomes that much harder. Each acute event permanently reduces renal reserve, lowering the threshold for the next crisis. What begins as a single admission can turn into ongoing hospitalizations, declining kidney function, and escalating costs — and all of this can happen before the patient realizes they have kidney disease. The subsequent burdens of extended ICU stays, skilled nursing facility placement, readmissions, and eventual dialysis initiation are substantial relative to the cost of intervening during the acute event itself.
The highest-cost, highest-leverage moment in kidney disease is not Stage 3 CKD in the clinic. It is in the OR or ICU, where kidney function is under maximum stress and the trajectory is still ours to influence. But the approach needs to change because chronic care models, by design, aren’t built to intervene.
The financial alignment is shifting
For most of the past decade, hospital economics did not reward protecting the kidney during acute events. Any sudden injury, damage or failure was managed as a complication, not prevented as a financial liability.
That is changing.
The TEAM model mandating participation for 741 hospitals as of January 2026 restructures financial accountability around the entire cardiac surgery episode. With 30–40 percent of cardiac surgery patients carrying CKD into the OR, acute kidney injury is no longer an incidental complication. Under TEAM, every consequence hits the margins directly: extended ICU stay, SNF placement, readmission, dialysis initiation. Quality performance adjusts payment by up to ±20 percent. There is no opt-out provision.
For health system operators, AKI in a CKD cardiac surgery patient is now a direct institutional liability, one the institution bears across the full episode of care.
The economic incentive to intervene during the acute event has never been more precisely aligned with the clinical opportunity to do so.
Where the opportunity sits
The lesson from the KCC evaluation is that kidney care doesn’t have an innovation problem. The real issue is one of timing.
During a high-risk clinical event, when kidney function is vulnerable but still recoverable, this is where a targeted intervention can produce enormous downstream economic benefits.
The health systems and innovators who recognize that distinction and act in that critical window may find that the biggest unrealized opportunity in kidney care has been hiding in plain sight.
Image: QAI Publishing/Universal Images Group via Getty Images
John Erbey, CEO and Founder of Roivios, leverages over 25 years of visionary leadership in the medical sector. With a Ph.D. from the University of Pittsburgh and Delta Omega membership, his research expertise drives Roivios’ innovative pursuits. Spearheading Roivios to pioneer kidney health management, John champions transformative solutions like the JuxtaFlow® Renal Assist Device (RAD), set to redefine global kidney care with a focus on sustaining or enhancing kidney function.
This post appears through the MedCity Influencers program. Anyone can publish their perspective on business and innovation in healthcare on MedCity News through MedCity Influencers. Click here to find out how.
